Media Citations

Our Reports

A wide portfolio of market research reports in the healthcare industry

latest reports

  • Companion Diagnostics Market (2nd Edition), 2019-2030

    Companion Diagnostics Market (2nd Edition), 2019-2030

    April 2019

    The introduction of personalized medicine has brought about a paradigm shift within the healthcare sector. Over the years, many cases have been identified where conventional treatment options have failed to demonstrate any therapeutic benefit. It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. In fact, adverse drug-related reactions / side effects are reported to be the fourth leading cause of death in the US.  To mitigate challenges associated with adverse drug reactions, there are multiple therapeutic products in the market, and many more under development, which have been tailored to effectively treat disease with unique molecular / genetic signatures.  Personalized therapies demand companion diagnostics to make physicians aware of patients’ unique genetic profiles, thereby, enabling them to make informed decisions. A study of nearly 200 unique pharmacological interventions, across 670 clinical trials, concluded that the likelihood of a lead compound passing through all the phases of clinical development and eventually getting approved is only 11%. The same study highlighted that correlating disease-specific biomarker data with therapeutic susceptibility and using this information to recruit patients for clinical research demonstrated a six fold increase in trial success rates.  It is also worth highlighting that companion diagnostic guided drug development efforts have been estimated to help reduce clinical trial costs by almost 60%.   Since the approval of the HercepTest™ (in 1998) for identifying patients for treatment with trastuzumab, over 50 companion diagnostics have been developed for various drugs. Further, several companies have also undertaken initiatives to develop biomarker-based therapeutics for other disease indications, such as infectious diseases, neurological disorders and metabolic disorders.  Industry stakeholders are forging strategic alliances with diagnostic developers to develop diagnostic solutions for a diverse array of drugs / therapies. Such initiatives are focused on improving clinical trial success rates, and subsequently optimizing R&D expenditure in the pharmaceutical industry. Scope of the Report The “Companion Diagnostics Market (2nd Edition), 2019-2030” report features an extensive study of the current market landscape and the likely adoption of these diagnostic tests over the next decade. The study features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of companies offering companion diagnostics, including information on their geographical location, corresponding drug(s) / drug class, affiliated biomarker, assay technique involved (in situ hybridization (ISH), immunohistochemistry  (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR) and others), therapeutic area (oncological disorders, infectious diseases, metabolic disorders, neurological disorders, inflammatory disorders and others) and the type of sample required (tumor tissue, blood, bone marrow and others). Detailed profiles of developers of companion diagnostics (shortlisted on the basis of the strength of product portfolio), featuring an overview of the company, its financial information (if available), a detailed description of companion diagnostics available / under development and recent collaborations. In addition, each profile includes a list of the likely strategies that may be adopted by these players to support future growth. A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands, taking into consideration several relevant aspects, such as strength of product portfolio, geographical presence / reach, recent collaborations, diversity in therapeutic focus and overall market position of each company. An analysis of the partnerships and collaborations pertaining to companion diagnostics, featuring a comprehensive set of analyses based on various parameters, such as the type of partnership, affiliated biomarkers, therapeutic areas and the most active players. A comparative analysis of the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain. A discussion on various steps of the development operations, namely research and development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing / sales activities, of a companion diagnostic and the cost requirements across each of the aforementioned stages. A comprehensive analysis of completed, ongoing and planned clinical trials featuring the key biomarkers across different type of therapies and cancer indications. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials. One of the key objectives of the report was to estimate the existing market size and the future opportunity for companion diagnostics developers, over the next decade. Based on multiple parameters, such as the disease incidence, adoption of companion diagnostic tests and the likely prices, we have provided informed estimates on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (oncological disorders (breast cancer, colorectal cancer, leukemia, lymphoma, melanoma, non-small cell lung cancer and ovarian cancer) and non-oncological disorders (Alzheimer’s disease and HIV/AIDs), [B] important assay techniques (in situ hybridization (ISH), immune histochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR) and others) and [C] key geographical regions (US, EU5, Japan, China and Australia). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.   The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more
  • Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030

    Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030

    April 2019

    Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (Humira,  Rituxan,  Lantus,  Avastin,  Herceptin  and Remicade ) and a robust pipeline of product / therapy candidates, the market is poised for significant growth in the coming years. It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics currently under development and biosimilars. The impending growth also indicates the rising importance of manufacturing capacity within the industry. The costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market. Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the CMOs in this domain. It is worth highlighting that, since 2000, more than115 new CMOs have been established in order to cater to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings. Despite the fact that the biopharmaceutical sector is amongst the most highly regulated industries, we expect the demand for core competencies to continue to drive sponsor companies to outsource various parts of their product development and manufacturing operations. Amidst tough competition, the availability of advanced tools and technologies is an important differentiating factor and is likely to grant a competitive edge to certain CMOs over other stakeholders.   Scope of the Report The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes: A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.  Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource. An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.  An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).  An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products. A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems (mammalian, microbial and others), [C] size of the company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: Astrid Brammer, Senior Manager Business Development, Richter-Helm Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie Christian Bailly, Director of CDMO, Pierre Fabre Claire Otjes, Assistant Marketing Manager, Batavia Biosciences David C Cunningham, Director Corporate Development, Goodwin Biotechnology  Dietmar Katinger, Chief Executive Officer, Polymun Scientific Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma  Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences Kevin Daley, Director Pharmaceuticals, Novasep  Mark Wright, Site Head, Grangemouth, Piramal Healthcare Nicolas Grandchamp, R&D Leader, GEG Tech Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals  Sebastian Schuck, Head of Business Development, Wacker Biotech  Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies  Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory Tim Oldham, Chief Executive Officer, Cell Therapies All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more
  • Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

    Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

    March 2019

    Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018, more than 50% of the global population lives with some form of chronic illness. In 2018, the global prevalence of diabetes (considered to be one of the fastest-growing clinical conditions) was estimated to be around 425 million; likewise, around 450 million people worldwide are suffering from some form of mental health problem and / or neurological disorder. In addition, the World Health Organization (WHO) reported that different forms of cancers account for about 0.6 million deaths annually in the US alone. Over the years, advances in cell biology and regenerative medicine have led to the development of various cell-based therapies, which claim to possess the potential to address several unmet needs related to the treatment of different chronic clinical conditions. However, there are certain evident challenges, such as scarcity of viable donors, inherent immunogenicity, complications related to supply of oxygen / essential nutrients to grafted cells, drug delivery limitations, and the need for frequent re-administration of cells, which have so far restricted the use of cell-based interventions. Extensive research on cell encapsulation strategies have enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices / carriers. Encapsulated therapy products offer a myriad of advantages, and have been shown to be capable of addressing existing concerns related to cell sourcing, obviating the need for complex surgical procedures, and enabling targeted drug delivery without the need for immunosuppressive follow-on regimens. In fact, since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in this domain. Stakeholders have also received significant support from both private and public investors. However, the commercial success of such products is still dependent on ongoing clinical studies, as no such therapy has yet been approved.   Scope of the Report The ‘Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030’ report features an extensive study of the current market landscape and the future potential of encapsulated cell therapies and affiliated technologies. It is worth mentioning that the study also provides insights on therapy products wherein other active drug substances have been encapsulated within living cells. Amongst other elements, the report features: A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications.  Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the in the foreseen future. An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation. A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials. An analysis of the partnerships that have been established in the domain in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals. An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. The report also features a detailed study on the various grants that have been awarded to research institutes in this field. An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus, type of cell, preclinical and clinical product portfolio, existing collaborations, and developer strength One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (metabolic and non-metabolic), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: Alexander Scheer (Chief Scientific Officer, Erytech Pharma) Manuel Pires (Junior Business Developer, Defymed) Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem) Mick McLean (Chief Executive Officer, Atelerix) Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals) William L Rust (Founder and Chief Executive Officer, Seraxis) Yuval Avni (Chief Executive Officer, Beta-O2 Technologies) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more

trending reports

press releases

  • Driven by the growing demand for biologics, the biopharmaceutical contract manufacturing market is expected to grow at an annualized rate of 8.1%, predicts Roots Analysis

    April 2019

    Roots Analysis has announced the addition of “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030” report to its list of offerings.  Souvik Mohanta, the principal analyst, stated, “Since 2000, more than 115 new CMOs, focused on biopharmaceuticals, have been established. The current biopharmaceutical contract manufacturing landscape features the presence of several established and emerging CMOs, with a diverse set of production capabilities.” The report presents opinions on several key aspects of the market. Among other elements, it includes:  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of over 235 CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee strength, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity. It is important to mention that majority of these firms offer services for proteins and peptides (140+), antibodies (125+), and vaccines (80+).  A discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. It is worth mentioning that antibody-based therapies, such as antibody drug conjugates (180+ candidates) and bispecific antibodies (150+ candidates), along with the more complex cell therapies (600+ candidates) and gene therapies (350+ candidates), require specialized infrastructure and handling expertise, thereby, causing innovator companies to rely more on specialty CMOs for their development and manufacturing. CMOs, such as (in alphabetical order, no selection criteria) apceth Biopharma, Brammer Bio, Cell and Gene Therapy Catapult, KBI Biopharma, Waisman Biomanufacturing and WuXi AppTec, claim to specialize in offering services for complex biologics. An informed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia)). It is worth mentioning that the current installed contract manufacturing capacity is over 4.5 million litres and is well distributed across various geographies. Currently, more than 50% of the capacity is captured by mammalian expression systems. The remaining share is occupied with microbial and other expression systems.  An analysis of the partnerships and collaborations focused on contract manufacturing of biologics, featuring a comprehensive set of analyses based on various parameters, such as the headquarters of partner companies, year of partnership, type of partnership, therapeutic area, most active players and geographical location. Over the last six years, close to 450 strategic partnerships have been inked between stakeholders in the biopharmaceutical contract manufacturing market. It is worth noting that 50% of these agreements were product-based deals signed for various purposes, including the development, manufacturing and commercialization of biologics. In addition, of the total number of partnership instances, majority were signed for cell therapies (25%) and antibodies (20%).  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired companies. Over 50 strategic mergers and acquisitions have recently taken place between different CMOs. It is important to highlight that 23% of the total acquisitions were signed for vaccines, followed by those signed for peptides / proteins (16%) and cell therapies (16%). An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing. Over 135 recent expansions were reported between 2013-2018; of these, 75% were focused on the addition of new facilities, or expansion of existing facilities.  An analysis of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products. Currently, the demand of biologics that are being marketed / investigated is primarily driven by patient segments of  oncological disorders and infectious disorders, accounting for ~40% of the total demand. A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs. With over 900 biosimilars under development, the market is highly likely to witness a surge in the demand for contract service providers.   A comprehensive market forecast analysis, based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, along with an informed estimate of the likely evolution of the market in the short to mid-term and mid to long-term, for the period 2019-2030. The report features likely distribution of the current and forecasted opportunity across the following segments: Commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)) Types of expression systems (mammalian, microbial and others)  Size of the company (small-sized, mid-sized and large / very large) Scale of operation (preclinical, clinical and commercial)  Key geographical regions (North America (the US and Canada), Europe (the UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)) North America currently holds the larger share (40%) of the market and is anticipated to grow at an annualized growth rate of 7.4%. However, markets in the Asia-Pacific are expected to grow at a significantly higher rate (8.9%), owing to inherent advantages, such as relatively low labor costs and less stringent regulatory constraints. A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. It is worth mentioning that one-third of the responders were at CXO level, 42% formed a part of senior management and 25% responders       A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource. The report features inputs from several eminent industry stakeholders. Mohanta remarked, “Most industry experts concur that the current bioprocessing challenges can be addressed / mitigated by the integration of emerging technologies, such as single-use technologies, resulting in enhanced productivity levels.” The report also features detailed transcripts of discussions held with the following experts: Astrid Brammer (Senior Manager Business Development, Richter-Helm Biotec) Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie) Christian Bailly (Director of CDMO, Pierre Fabre) Claire Otjes (Assistant Marketing Manager, Batavia Biosciences) David C Cunningham (Director Corporate Development, Goodwin Biotechnology)  Dietmar Katinger (Chief Executive Officer, Polymun Scientific)  Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma) Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences) Kevin Daley (Director Pharmaceuticals, Novasep) Mark Wright (Site Head, Grangemouth, Piramal Healthcare) Nicolas Grandchamp (R&D Leader, GEG Tech) Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals) Sebastian Schuck (Head of Business Development, Wacker Biotech) Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) Tatjana Buchholz (Marketing Manager, PlasmidFactory) and Marco Schmeer (Project Manager, PlasmidFactory) Tim Oldham (Chief Executive Officer, Cell Therapies) The research covers detailed profiles and assesses service portfolios of several companies (illustrative list below); each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as an informed future outlook. 3P Biopharmaceuticals Abzena Albany Molecular Research Baxter International BioVectra BioXcellence™ (Boehringer Ingelheim) Catalent Celonic CEPiA - Sanofi Charles River Laboratories ChemPartner Cobra Biologics CordenPharma Cytovance Biologics Grand River Aseptic Manufacturing IDT Biologika Kemwell Biopharma LFB Biomanufacturing Lonza Meridian Life Science Patheon Pfizer CentreOne Piramal Pharma Solutions PX'Therapeutics Thermo Fisher Scientific Vetter Pharma International WuXi Biologics For additional details, please visit  https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html  or email sales@rootsanalysis.com  Contact: Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com

    ...read more
  • Next Generation Contact Lenses and Visual Prostheses Market Projected to Grow at an Annualized Rate of 20%, predicts Roots Analysis

    March 2019

    Roots Analysis has announced the addition of “Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030” report to its list of offerings.  Natasha Thakur, the principal analyst, stated, “Advancements in the domain of ophthalmology continue to expand the range of potential application areas for contact lenses. Presently, over 55 novel ophthalmic products have been developed or are being developed for the treatment of various ophthalmological disorders, diagnosis / monitoring of diseases and for restoring vision in the blind. The ongoing efforts to innovate in this domain are evident from the fact that more than 7,500 patents have been granted / filed since 2013.” The report presents opinions on several key aspects of the market. Among other elements, it includes:  A detailed assessment of the current market landscape of novel ophthalmic products, highlighting the different categories of contact lenses and visual prostheses (bionic eye technologies) developed / being developed by various players across the world. It features information on the purpose of development (therapeutic, drug delivery, and diagnosis / monitoring), current development status (marketed or under development), target indication(s), type of product (bandage contact lenses, contact lenses or implants), type of organization (industry or non-industry) and location of company headquarters. The market landscape is characterized by the presence of both industry and non-industry players. Most of the industry players are focused on developing therapeutic contact lenses, whereas majority of the academic groups are engaged in the development of smart contact lenses for diagnostic / monitoring purposes. Examples of companies with marketed products include (in alphabetical order, no selection criteria) Alcon, Bausch & Lomb, ChromaGen Vision, EyeYon Medical, HumanOptics, Implandata Ophthalmic Products, Johnson & Johnson Vision Care, OPHTEC, SENSIMED and VisionCare Ophthalmic Technologies. An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely ChromaGen™, CUSTOMFLEX® ARTIFICIALIRIS, EYEMATE®, Hyper-CL™, Implantable Miniature Telescope and SENSIMED Triggerfish®. An in-depth analysis of close to 7,500 patents that were granted / filed related to next generation contact lenses and visual prostheses during 2013 to October 2018, highlighting the prevalent and emerging related to the innovation in this domain. The analysis takes into consideration the type of patent, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation. It is worth mentioning that, of the total, 64% patents have been filed / granted in the US.  The top patent assignees include (in decreasing order of number of patents filed / granted) Novartis, Massachusetts General Hospital, Allergan, University of California, Google, Massachusetts Institute of Technology, University of Colorado, and University of Illinois Ophthalmology. An analysis of the partnerships that have been established in this domain, covering R&D agreements, product development agreements, product commercialization agreements, service alliance and acquisitions; the analysis is based on multiple parameters, such as the type of agreement, type of organization, and focus area in terms of product application and target indication. It is worth noting that, product development agreements were the most popular type of deals inked in this domain, representing 46% of the total number of collaborations. Examples of product development agreements inked in the last two years include the collaborations between the University of Texas and Seoul National University, University of Liverpool and Moorfields Eye Hospital, St Paul's Eye Hospital and UltraVision CLPL, and Oregon State University and Civil Aviation University of China. An analysis on the emerging trends and the growing popularity of next generation contact lenses and visual prostheses, as observed on the social media platform, Twitter. Over 2,300 tweets have been posted between 2013 and 2018 (till mid-October).  A detailed list of key opinion leaders (KOLs) in this domain, featuring a 2X2 analysis to assess the relative experience of certain individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs based on number of publications, number of citations, number of clinical trials, number of affiliations and extent of professional network. Examples of top hospitals, research institutes and universities that were found to be actively involved in two or more than two clinical trials related to next generation contact lenses and visual prostheses include (in the decreasing order of their participation in clinical trials) Harbor-UCLA Medical Center, Rabin Medical Center, Clinic Saint Jean, Eye Physicians of Long Beach and Quinze-Vingts National Ophthalmology Hospital. A robust market forecast analysis, highlighting the current value and future potential of next generation contact lenses and visual prostheses market. Based on parameters, such as the target patient population, price of the lenses and the likely adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features a detailed segmentation of the present and anticipated future opportunity based on [A] type of product (contact lenses and visual prostheses) [B] purpose of development of contact lenses (therapeutic, drug delivery and diagnosis / monitoring) [C] key disease indications (glaucoma, diabetes, AMD, retinitis pigmentosa and others) and [D] geography (North America, EU5 and Asia-Pacific). Therapeutic contract lenses represent 80% of approved novel ophthalmic lenses; we expect such products to dominate the overall contact lenses market in the near future as well. At the same time, contact lenses being developed for drug delivery and diagnostics are likely to grow at relatively higher CAGR between 2019 to 2030. The present and upcoming opportunities for novel ophthalmic products are spread across diverse therapeutic areas. As more products receive approval, glaucoma is anticipated to drive the maximum revenues from sales of next generation contact lenses and / or visual prostheses, followed by diabetes and AMD, in 2030. The report features inputs from a number of eminent industry stakeholders. Thakur remarked, “Most of the experts we spoke to agreed that the conventional methods of administering drugs into the eye are less efficient as only 5% of topically administered drugs are able to penetrate the cornea. On the other hand, drug-eluting contact lenses have been shown to be more efficient as compared to conventional methods of drug delivery to the eye, leading to a lower number of side effects.” The report features detailed transcripts of discussions held with the following experts: Michal Shavit (Head of Sales and Marketing, EyeYon Medical)  Mark E. Byrne (Co-Founder and Chief Technical Officer, OcuMedic)  Praful Doshi (Founder, Chief Executive Officer and Chief Technical Officer, Leo Lens Technology)  The research also includes brief technology profiles of the following players: EyePrint Prosthetics University of Washington  Leo Lens Technology Baylor College of Medicine  iBIONICS For additional details, please visit  https://www.rootsanalysis.com/reports/view_document/next-generation-contact-lenses-and-visual-prostheses-market-2019-2030/244.html or email sales@rootsanalysis.com Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 gaurav.chaudhary@rootsanalysis.com

    ...read more
  • Driven by a growing pipeline of drugs targeting various chronic disorders, the large volume wearable injectors market is anticipated to grow at a rapid pace (CAGR ~40%), predicts Roots Analysis

    March 2019

    Roots Analysis has announced the addition of “Large Volume Wearable Injectors Market (4th Edition), 2018-2030” report to its list of offerings. Harsimran Kaur, the principal analyst, stated, “The large volume wearable injectors continue to retain the interest of both drug developers and medical device manufacturers. This can be attributed to the various benefits offered by these devices. In fact, over 50 devices are currently under development / approved for the delivery of both insulin and non-insulin drugs.” The report presents opinions on several key aspects of the market. Among other elements, it includes: A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. It is worth highlighting that devices designed for administration of non-insulin drugs have a high storage capacity and are being developed for delivery of high viscosity formulations. In fact, around 17% of such devices have been designed to hold 10-15 ml of drug formulation, while 23% claim to offer a maximum storage capacity of more than 15 ml. A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). Close to 80 drug / drug candidates demonstrate the potential to be delivered via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. Of these, 90% are biologics and 10% are small molecules. These drugs (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems. A comprehensive product competitiveness analysis of all large volume wearable injectors, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application, and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices. Elaborate profiles of prominent product developers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products. More than 10 drug device combinations are currently being evaluated for delivery of non-insulin drugs. Of these, two are already approved by the USFDA; these are Neulasta® (pegfilgrastim) OnPro™ Kit (Amgen / Insulet) and Pushtronex™ System (Amgen / West Pharmaceuticals). An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors, since 1984. It also highlights the key parameters associated with the patents, including information on patent type, patent offices, Cooperative Patent Classification (CPC) classification, emerging areas (in terms of number of patents filed / granted) and leading industry players (in terms of size of intellectual property portfolio). Close to 2,000 patents pertaining to these devices have been filed till September 2018. An analysis of these patents reveals that automated self-injection devices, with advanced features, are gradually gaining traction amongst patients with chronic disorders. A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis is based on tweets posted on the platform from 2013 to 2018. A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. The study includes short descriptions of the manufacturing services provided by contract service providers in the manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings. A robust opportunity analysis highlighting the market for large volume wearable devices for delivery of non-insulin drugs. The market is anticipated to grow at an annualized rate of close to 40% between 2018 and 2030. It is worth noting that disposable injectors are likely to capture over 50% of the market share due to the safety concerns reported by the use of reusable injectors. Further, over 60% share of revenues is anticipated to be distributed between North America and Europe. However, certain counties in Asia Pacific are likely to grow at a faster rate as compared to other regions over the coming decade; this can be attributed to the increasing incidence of chronic disorders in these regions and a relatively less stringent regulatory environment.   Kaur further remarked, “The innovation in the field is primarily being driven by start-ups / small companies. Of all the companies developing large volume wearable injectors for non-insulin drugs, 50% are based in North America. Examples of firms based in this region include (in alphabetical order, no selection criteria) Enable Injections, Medipacs, SteadyMed Therapeutics, scPharmaceuticals and West Pharmaceutical Services. Examples of start-ups based in other geographical regions that have undertaken initiatives in this domain include (in alphabetical order, no selection criteria) Debiotech, Subcuject, ViCentra, Weibel CDS and Eoflow. In addition, a number of established companies are also making substantial contributions in this field; prominent players include (in alphabetical order, no selection criteria) 3M, Becton Dickinson, Insulet, West Pharmaceutical Services and Ypsomed. Historical and current uptake trends clearly demonstrate the growing popularity of these devices. With many developers striving to incorporate more user-friendly and advanced features in their devices, the adoption of large volume wearable injectors is expected to steadily increase in the mid-long term.” The report also features inputs from a number of eminent industry stakeholders, with detailed transcripts of discussions held with the following individuals: Menachem Zucker (Vice President and Chief Scientist, Elcam Medical) Mike Hooven (President and Chief Executive Officer, Enable Injections) Mark Banister (Chief Executive Officer, Medipacs) Pieter Muntendam (President and Chief Executive Officer, scPharmaceuticals) Mindy Katz (Director of Product, Sorrel Medical) Jesper Roested (Chief Executive Officer, Subcuject) Graham Reynolds (Vice President & General Manager, Global Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) The research covers detailed profiles and assesses product portfolios of several companies, including (illustrative list, no selection criteria): Becton Dickinson Bespak Insulet Medtronic Roche Sonceboz Enable Injections Sensile Medical SteadyMed Therapeutics West Pharmaceutical Services Weibel CDS Cellnovo CeQur Debiotech Eli Lilly PharmaSens SOOIL Development Tandem Diabetes Care   For additional details, please visit  https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html or email sales@rootsanalysis.com                                                                                                                                                                                                           Contact: Gaurav Chaudhary gaurav.chaudhary@rootsanalysis.com +1 (415) 800 3415 +44 (122) 391 1091

    ...read more

The Roots Analysis Edge

200 +

Reports

40 +

Major Pharma Markets

400 +

Clients

50 +

Analytical Frameworks

Consulting

Market insights from across the industry value chain tailored to meet your business needs

  • All
  • Drug Discovery
  • Research & Development
  • Commercialization
  • Affilated services
  • Pipeline Tracking

  • Therapy Area Assessment

  • Clinical Trial Tracking

  • KOL Selection

  • Publication Analysis

  • Investment Analysis

  • Market Assessment

  • Deal Tracking

  • Competitive Profiling

  • Commercial Strategy and Business Development

Why Choose Us?

We are your partners with no equity

We fit in your budget

We love what we do

chance to prove ourselves

Best in class quality of work

Most trusted consulting partner in the industry